计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S647037-5mg |
5mg |
期货 ![]() |
| |
| S647037-10mg |
10mg |
期货 ![]() |
| |
| S647037-50mg |
50mg |
期货 ![]() |
| |
| S647037-100mg |
100mg |
期货 ![]() |
|
| 规格或纯度 | ≥98% |
|---|---|
| 英文名称 | SRPKIN-1 |
| 生化机理 | SRPKIN-1 是一种共价且不可逆的 SRPK1/2 抑制剂,其 IC 50 s 分别为 35.6 和 98 nM。抗血管生成作用。 |
| 储存温度 | -20°C储存,充氩,干燥 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC 50 s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect In Vitro SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout. ? SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Ba/F3 cells Concentration: 0-10000 nM Incubation Time: 72 h Result: Potently decreased the level of SR phosphorylation in a dose-dependent manner, leading to increased VEGF-A165b RNA as well as protein even at a dose of 200 nM. In Vivo SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 50 nM, 300 nM, 1 μL Administration: Intravitreal injection, 5 times Result: SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area . Form:Solid IC50& Target:IC50: 35.6 nM (SRPK1), 98 nM (SRPK2) |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 未知 |
|---|---|
| IIUPAC Name | 3-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-5H-benzo[b]carbazol-8-yl)benzenesulfonyl fluoride |
| INCHI | 1S/C27H21FN2O3S/c1-4-16-12-21-22(13-20(16)17-6-5-7-18(11-17)34(28,32)33)27(2,3)26-24(25(21)31)19-9-8-15(14-29)10-23(19)30-26/h5-13,30H,4H2,1-3H3 |
| InChi Key | TWKWEBMGDALHPN-UHFFFAOYSA-N |
| Smiles | CCC1=CC2=C(C=C1C3=CC(=CC=C3)S(=O)(=O)F)C(C4=C(C2=O)C5=C(N4)C=C(C=C5)C#N)(C)C |
| Isomeric SMILES | CCC1=CC2=C(C=C1C3=CC(=CC=C3)S(=O)(=O)F)C(C4=C(C2=O)C5=C(N4)C=C(C=C5)C#N)(C)C |
| PubChem CID | 135324340 |
| 分子量 | 472.53 |
| 溶解性 | DMSO : ≥ 110 mg/mL (232.79 mM) |
|---|---|
| 分子量 | 472.500 g/mol |
| XLogP3 | 6.300 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 472.126 Da |
| 单同位素质量Monoisotopic Mass | 472.126 Da |
| 拓扑极表面积Topological Polar Surface Area | 99.200 Ų |
| 重原子数Heavy Atom Count | 34 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 966.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |